Daiichi Sankyo US

#ASCO26NEWS: Throughout the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Daiichi Sankyo US will present: - More than 25 abstracts across our oncology portfolio in breast, gastric, ovarian, urothelial and salivary cancers, as well as acute myeloid leukemia - Early phase trials-in-progress featuring potential medicines with novel mechanisms highlight the company’s commitment to identification of new breakthrough generating technologies for patients with cancer https://bit.ly/4uyjSwb Click the link to learn more and visit us during #ASCO26. #OncologyNews 

It’s a simple but powerful idea. “Divide your day into three sets of eight. Eight hours to sleep. Eight hours to work. Eight hours to live and make a difference.”     John Ruggiero leads with that mentality. He knows what it means to receive a cancer diagnosis — both personally and as someone who works in this space every day. His experience shaped a deeper understanding of what it truly means to put patients at the center of what we do.    Behind every medicine is a personal story of the people – like John - who bring purpose, precision, and compassion to the work we do at Daiichi Sankyo.    🎥 Watch John’s story and discover his crafts of empowerment, positioning, and storytelling — and how they drive meaningful impact for the patients and families we serve.    📣 Learn more about our innovative medicines and the milestones shaping the future of patient care: https://bit.ly/3QXa8wy   #WhereCraftMeets #PatientCentricity #Innovation 

Watch to see how our 2035 Vision is shaping what’s next. Our ambition is bold: become a top five oncology company and earn recognition as a trusted healthcare innovator, transforming the lives of people through science and technology. #ICYMI: Explore the four key initiatives of our new Five-Year Business Plan: https://bit.ly/4npuSJq #DaiichiSankyoVision2035

Heading to ASCO? Let’s connect and talk about how Daiichi Sankyo could be your next career destination. Sign up to speak with a recruiter and find your place here.

“Why didn’t I notice it sooner?” While Michele Schmidt’s work as a registered nurse provided perspective and knowledge during her father’s stage four cholangiocarcinoma diagnosis, it also left her grappling with difficult questions. Now, as an R&D leader at Daiichi Sankyo, Michele uses her personal experience to think holistically about new medicine development and reimagine a world where survival isn’t limited to certain cancers. 👉 Learn more about Michele’s inspiring story. https://bit.ly/4tM8BaH #PatientCentricity #WhereCraftMeets #CareerPaths 

We’re excited to cheer on our Daiichi Sankyo colleagues recognized as HBA 2026 Rising Stars & Luminary Award winners—including Mareike Lochte, Kelley Janosko, and yuri chae! 🎉   These honors from the Healthcare Businesswomen’s Association (HBA) celebrate leaders who are making an impact today and helping shape what’s next for healthcare—through fresh ideas, inclusive leadership, and a commitment to lifting others along the way.   At Daiichi Sankyo, we believe recognition like this goes beyond individual achievement. It reflects a shared commitment to expanding opportunity and fostering an environment where diverse perspectives and bold ideas can thrive—for the benefit of patients and communities worldwide.   Congratulations to our honorees, and to all of the 2026 HBA Rising Stars and Luminary Award recipients, whose leadership and impact continue to move our industry forward.   #DSProud #AscendWithHBA

Behind every medicine is a personal story of the people who bring purpose, precision, and compassion to the medicines we create at Daiichi Sankyo.   Michele Schmidt, Head of Global Asset Strategy & Portfolio Management, shares how her journey - from registered nurse to R&D leader to caregiver - deepened her commitment to keeping patients and families at the center. After her father’s diagnosis with a rare form of cancer, she felt “Well, that’s the way we always do it.” was not enough when patients are waiting. 🎥 Watch Michele Schmidt’s story and discover her craft of reimagining - connecting strategy, science, and the patient experience to help drive what’s next. 📣 Learn more about our innovative medicines and the milestones shaping the future of patient care:  https://bit.ly/4sbSjqS #WhereCraftMeets #Innovation #PatientCentricity 

This International Women’s Day, we’re celebrating the power of giving - to uplift, to mentor, and to create opportunity - because progress in science, medicine, and patient care doesn’t happen alone. At Daiichi Sankyo, progress happens when we invest in one another: sharing knowledge, opening doors, and championing women at every stage of their journey. We see every day how mentorship, advocacy, and opportunity help women advance innovation and strengthen the teams behind life-changing medicines. When we give support, opportunity, and advocacy, we all gain. When we #GiveToGain, we build a future where more voices shape what’s possible. 💙 Who’s a woman who has helped you grow? Tag her and share how giving made a difference. #IWD2026 #GiveToGain #DSProud

Gynecologic cancers are often difficult to detect early — making deeper biological understanding and new treatment approaches critical. Read how Daiichi Sankyo US is evaluating the potential of HER2-directed therapies in endometrial and ovarian cancers, with a focus on advancing more personalized options for patients. 🔗 https://bit.ly/4rNznil #GynecologicCancer #EndomertialCancer #OvarianCancer